These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 23590397)
61. What is ventilator-associated pneumonia and why is it important? Kollef MH Respir Care; 2005 Jun; 50(6):714-21; discussion 721-4. PubMed ID: 15913464 [TBL] [Abstract][Full Text] [Related]
62. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Sotgiu G; Aliberti S; Gramegna A; Mantero M; Di Pasquale M; Trogu F; Saderi L; Blasi F Respir Res; 2018 Oct; 19(1):205. PubMed ID: 30352588 [TBL] [Abstract][Full Text] [Related]
63. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Arnold HM; Sawyer AM; Kollef MH Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038 [TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339 [TBL] [Abstract][Full Text] [Related]
65. [A retrospective cohort study of the influence of time of hospital-acquired pneumonia onset on pathogen constitution]. Hu BJ; Wei L; Zhang XZ; Tang YC; Ni YX; Li YM; Guo JQ; Hu YJ; Zhang KX; Yang L Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):112-6. PubMed ID: 15854394 [TBL] [Abstract][Full Text] [Related]
66. Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. Weiss E; Essaied W; Adrie C; Zahar JR; Timsit JF Crit Care; 2017 Jun; 21(1):162. PubMed ID: 28655326 [TBL] [Abstract][Full Text] [Related]
67. [Antibiotic treatment of pneumonia - what's at CAP, HAP and VAP to consider?]. Welte T Drug Res (Stuttg); 2014 Nov; 64 Suppl 1():S11-2. PubMed ID: 25423417 [No Abstract] [Full Text] [Related]
68. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149 [TBL] [Abstract][Full Text] [Related]
69. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Kim A; Kuti JL; Nicolau DP Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018 [TBL] [Abstract][Full Text] [Related]
70. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Muscedere JG; Day A; Heyland DK Clin Infect Dis; 2010 Aug; 51 Suppl 1():S120-5. PubMed ID: 20597661 [TBL] [Abstract][Full Text] [Related]
71. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Saravolatz LD; Stein GE; Johnson LB Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022 [TBL] [Abstract][Full Text] [Related]
72. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Vidaillac C; Rybak MJ Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461 [TBL] [Abstract][Full Text] [Related]
73. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. Rattanaumpawan P; Lorsutthitham J; Ungprasert P; Angkasekwinai N; Thamlikitkul V J Antimicrob Chemother; 2010 Dec; 65(12):2645-9. PubMed ID: 20876621 [TBL] [Abstract][Full Text] [Related]
74. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective. Laessig KA Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659 [TBL] [Abstract][Full Text] [Related]
75. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Song JH; Am J Infect Control; 2008 May; 36(4 Suppl):S83-92. PubMed ID: 18468550 [TBL] [Abstract][Full Text] [Related]
76. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH; Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995 [TBL] [Abstract][Full Text] [Related]
77. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. Arias CA; Singh KV; Panesso D; Murray BE J Antimicrob Chemother; 2007 Sep; 60(3):594-8. PubMed ID: 17606481 [TBL] [Abstract][Full Text] [Related]
78. Management of ventilator-associated pneumonia. Diaz E; Ulldemolins M; Lisboa T; Rello J Infect Dis Clin North Am; 2009 Sep; 23(3):521-33. PubMed ID: 19665081 [TBL] [Abstract][Full Text] [Related]